- Home
- SD vs CRMD Comparison
SD vs CRMD Comparison
Compare SD & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | CRMD |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.0M | 590.7M |
| IPO Year | 2006 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SD | CRMD |
|---|---|---|
| Price | $14.27 | $7.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 321.4K | ★ 897.3K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | 12.43 | ★ 780.00 |
| EPS | ★ 1.22 | 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $25.99 | $8.13 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ $10.38 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $11.20 | $6.13 |
| 52 Week High | $18.45 | $13.02 |
Technical Indicators
Market Signals| Indicator | SD | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 39.11 |
| Support Level | $13.84 | $7.08 |
| Resistance Level | $14.47 | $7.44 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 88.52 | 28.73 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.